PAION AG: Management Board Change
Advertisement
The biopharmaceutical company PAION AG announced that Dr Gavin Kilpatrick has stepped down from his position as a member of the Management Board and will be leaving the company on 30 April 2011. In his role as Chief Scientific Officer, Dr Kilpatrick was responsible for production, pre-clinical development, drug discovery, project management and intellectual property. Dr Wolfgang Söhngen, PAION’s CEO, and Dr Mariola Söhngen, PAION’s CMO, will take over these responsibilities in the future.